ERBB2 and breast cancer: The standard of practice for HER2/neu-positive breast cancer is 1 year of adjuvant trastuzumab with chemotherapy.13 However, shorter regimens that consist of 9 weeks of trastuzumab with chemotherapy have been reported from Finland and are considered highly cost effective.14 This protocol is being adopted by most African physicians because of cost constraints.